文献速递中药与中成药合理使用中医内科

桑白皮总黄酮提取物中四种成分在糖尿病与正常大鼠体内的比较药代动力学

Comparative pharmacokinetics of four major compounds after oral administration of Mori Cortex total flavonoid extract in normal and diabetic rats.
PubMed 文献 · Front Pharmacol · 2023-03-01

本研究建立UPLC-MS/MS法同时测定大鼠血浆中桑色素、桑辛素、伞形花内酯和桑皮苷A,并比较口服桑白皮总黄酮提取物后正常与糖尿病大鼠的药代动力学差异。方法学验证良好,糖尿病大鼠中桑色素、桑辛素、伞形花内酯和桑皮苷A的AUC(0-t)和Cmax均显著升高。

要点

  • 建立的UPLC-MS/MS法可同时测定桑白皮总黄酮提取物中四种成分。
  • 糖尿病大鼠中桑色素和桑辛素的AUC(0-t)与Cmax较正常大鼠明显增加。
  • 伞形花内酯和桑皮苷A在糖尿病大鼠中的AUC(0-t)与Cmax也显著升高(p<0.05)。

核心结论

  • 所建立的UPLC-MS/MS方法成功用于正常和糖尿病大鼠的药代动力学研究。
  • 糖尿病状态下四种成分的暴露量均显著高于正常大鼠。

研究设计与样本

  • 研究建立UPLC-MS/MS方法测定大鼠血浆中桑色素、桑辛素、伞形花内酯和桑皮苷A。
  • 采用蛋白沉淀法预处理样品,以芫花素为内标。
  • 比较正常大鼠与糖尿病大鼠口服桑白皮总黄酮提取物后的药代动力学差异。

主要发现

  • 桑色素在正常大鼠的AUC(0-t)为501.3 ± 115.5 ng/mL*h,Cmax为127.8 ± 56.0 ng/mL;糖尿病大鼠分别为717.3 ± 117.4 ng/ml*h和218.6 ± 33.5 ng/ml。
  • 桑辛素在正常大鼠的AUC(0-t)为116.4 ± 38.2 ng/ml*h,Cmax为16.8 ± 10.1 ng/mL;糖尿病大鼠分别为325.0 ± 87.6 ng/mL*h和39.2 ± 5.9 ng/ml。
  • 伞形花内酯和桑皮苷A在糖尿病大鼠的AUC(0-t)和Cmax也显著增加(p<0.05)。

关键数值与推荐

  • 日内和日间精密度均小于12.5%,准确度范围为-8.1%至3.5%。
  • 提取回收率大于88.5%,未观察到明显基质效应。

临床怎么用

  • 提示糖尿病状态可能改变桑白皮总黄酮中四种成分的体内暴露,临床用药时需关注病理状态对药代动力学的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Mori Cortex has been used in traditional Chinese Medicine as an antidiabetic agent. The aim of this study was to establish a UPLC-MS/MS method for simultaneous determination of morin, morusin, umbelliferone and mulberroside A in rat plasma and investigate the pharmacokinetics differences between normal and diabetic rats following oral administration of Mori Cortex total flavonoid extract. Methods: Samples were pre-treated by protein precipitation and genkwanin was used as internal standard. Chromatographic separation was performed using a Hypersil GOLD C18 column (50 mm × 2.1 mm, 3 μm). The mobile phase consisted of acetonitrile and water (containing 0.1% formic acid) in gradient mode at a flow rate of 0.5 ml/min. The transitions of m/z 300.9→107.1, m/z 419.3→297.1, m/z 160.9→77.0, m/z 567.1→243.2 and m/z 283.1→268.2 were selected for morin, morusin, umbelliferone, mulberroside A and internal standard, respectively. Results: The intra- and inter-day precision for analytes were less than 12.5% and the accuracy ranged from -8.1% to 3.5%. The extraction recovery was >88.5% and no obvious matrix effect was observed. The AUC (0-t) and C max of morin were 501.3 ± 115.5 ng/mL*h and 127.8 ± 56.0 ng/mL in normal rats and 717.3 ± 117.4 ng/ml*h and 218.6 ± 33.5 ng/ml in diabetic rats. Meanwhile, the AUC (0-t) and C max of morusin were 116.4 ± 38.2 ng/ml*h and 16.8 ± 10.1 ng/mL in normal rats and 325.0 ± 87.6 ng/mL*h and 39.2 ± 5.9 ng/ml in diabetic rats. For umbelliferone and mulberroside A, the AUC (0-t) and C max also increased significantly in diabetic rats (p < 0.05). Discussion: The validated method was successfully applied to the pharmacokinetic study in normal and diabetic rats.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xiong S, Li X, Chu H, et al. Comparative pharmacokinetics of four major compounds after oral administration of Mori Cortex total flavonoid extract in normal and diabetic rats. Front Pharmacol. 2023. PMID: 36937873. doi:10.3389/fphar.2023.1148332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。